KEYNOTE‐811: Potential to revise first‐line therapy for metastatic human epidermal growth factor receptor 2‐positive gastric cancer

Abstract

Abstract The first‐line therapy pattern transition of metastatic HER2‐positive gastric cancer is shifting. The KEYNOTE‐811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2‐targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD‐L1 CPS≥1. In the future, the first‐line therapy pattern of metastatic HER2‐positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials.

Keywords

• chemotherapy
• gastric cancer
• immunotherapy